search
Back to results

Efficiency Assessment of BREFORM. A Multicentric Stepped-wedge Randomized Control Trial. (BREFORM)

Primary Purpose

Schizophrenia

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
control group
Intervention group
Sponsored by
Hôpital le Vinatier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Schizophrenia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • people over 18yo
  • first-degree relatives (parents, siblings, children) or spouse of the patient
  • primary caregiver of a patient with schizophrenic disorders or first psychotic episode (DSM5)
  • consenting to participate to the study

Exclusion Criteria:

  • mental disorder on Axis I
  • having already benefited from a family intervention such as psychoeducation
  • caring for several people with severe psychiatric disorders
  • receiving income for the caring activities
  • being legally responsible of the patient
  • having difficulty understanding fluent French
  • illiterate

Sites / Locations

  • Hopital VinatierRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Control group

intervention group

Arm Description

The design is a stepped-wedge cluster randomized controlled trial. The study will be conducted in 9 centers (clusters) and will be conducted in 6 successive phases of 4 months each. During the first period, groups will be in the control period, then sequentially and according to a randomly defined order, at each time, one group will go into the intervention period after a transition period of 4 months allowing the intervention to be deployed (training of three health professionals for each center and then implementation of the BREF program). Thus, each cluster will belong successively to the control group and the intervention group. During the control period, caregivers will be supported according to the usual practices of each center. During the intervention period, the BREF program will be offered to all eligible caregivers.

Thus, each cluster will belong successively to the control group and the intervention group. During the intervention period, the BREF program will be offered to all eligible caregivers.

Outcomes

Primary Outcome Measures

Changes in the severity of caregiver burden between V1 and V4 by the Zarit Burden Inventory scale (ZBI)
The ZBI consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. Higher scores indicate greater burden. A score of 17 or more was considered high burden.

Secondary Outcome Measures

Changes in caregiver burden severity at V1,V2 and V3 by the Zarit Burden Inventory (ZBI) scale
The ZBI consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. Higher scores indicate greater burden. A score of 17 or more was considered high burden.
Evolution of the caregivers' perceived-stress between V1, V2, V3, V4 by the Perceived Stress Scale-14 (PSS-14)
Total score of the PSS can be obtained by summing the 14 items' scores . The total score ranges from 0 to a maximum of 56, a higher score indicating a higher level of perceived stress.
Evolution of the caregivers' mood between V1, V2, V3, V4 by the Center for Epidemiologic Studies-Depression Scale (CES-D)
The CES-D consists of 20 items in a self-report format measuring depressive symptoms experienced in the past week on a 4-point Likert scale ranging from 0 (rarely or none of the time) to 3 (most or all of the time). Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. ... PHQ-9 score ≥10 had a sensitivity of 88% and a specificity of 88% for major depression.
Evolution of the caregivers' family functioning between V1, V2, V3, V4
Assessed by the Family Assessment Device scale (FAD)
Evolution of the caregivers' quality of life between V1, V2, V3, V4
Assessed by the Schizophrenia CareGiver Quality of Life scale (S-CGQoL)
Evolution of the caregivers' sense of competence between V1, V2, V3, V4
assessed by the Sense of Competence Questionnaire scale (SCQ)
Evolution of the caregivers' number of consultations with the general practitioner (GP)
Change in number of consultations with the general practitioner (GP) n the 12 months prior to inclusion compared to the 12 months following inclusion
Evolution of the caregivers' number of days off work
Change in number the caregivers' number of days off work in the 12 months prior to inclusion compared to the 12 months following inclusion
Evolution of the caregivers' number of days on long-term leave or disability
Change in the number of long-term leaves of absence or disability related to the caregiver situation in the 12 months prior to inclusion compared to the 12 months following inclusion
Evolution of the caregivers' number of work days
Change in the number of work days related to the caregiver situation in the 12 months prior to inclusion compared to the 12 months following inclusion
Evolution of the caregivers' willingness to pay someone to replace them in their caring activities during one hour
Change in caregivers' willingness to pay someone to replace them in their caregiving activities for one hour in the 12 months prior to inclusion versus 12 months after inclusion.
Evolution of the caregivers' number of suicide attempts assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
The Columbia Suicide Severity Rating Scale (C-SSRS) is a measure used to identify and assess individuals at risk for suicide. Questions are phrased for use in an interview format, but can be completed as a self-report measure if necessary. The score is created at each assessment for each patient and is used for determining treatment emergence. Suicidal Ideation Score: The maximum suicidal ideation category (1-5 on the C- SSRS) present at the assessment. Assign a score of 0 if no ideation is present.
caregivers' satisfaction
questionnaire
Evolution of the caregivers' living status (shared or non-shared household) between V1, V2, V3, V4
questionnaire
Evolution of the caregivers' informal caregiving activities between V1, V2, V3, V4
questionnaire
Evolution of the caregivers' number of hours spent providing informal caregiving between V1, V2, V3, V4
questionnaire
Evolution of the patients' psychotic symptoms severity between baseline and 12 months after baseline assessed by the Positive And Negative Syndrome Scale (PANSS)
PANSS items are rated on a 7-point scale (1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, and 7=extreme); because the absence of symptoms is equal to 1 point, the lowest possible total score on both PANSS scales is 7.
Evolution of the patients' functioning level between baseline and 12 months after baseline
Assessed by the Global Assessment of Functionning scale (GAF)
Evolution of the patients' functioning level assessed by the Personal and social Performance scale (PSP)
The patient's degree of severity in the four domains is to be rated on a six-point scale from absent (which means no problems on this dimension) over mild, manifest, marked, severe to very severe difficulties in the given area. Out of the ratings on the four subdimensions, one total score on a 100-point scale can be created. A variation of eight points is already to be classified as a clinically relevant difference. The items "self-care" and "disturbing and aggressive behavior" are of greater concern for patients with acute
Evolution of the patients' quality of life between baseline and 12 months after baseline
Assessed by the Schizophrenia-quality of Life scale (S-QoL)
Evolution of the patients' clinical severity between baseline and 12 months after baseline
Assessed by the Clinical Global Impression (CGI)
Evolution of the patients' depressive symptoms between baseline and 12 months after baseline
Assessed by the Calgary Depression Scale for Schizophrenia scale (CDSS)
Evolution of the patients' relapse risk factors between baseline and 12 months after baseline
Composite score assessed by the Medication Adherence Rating Scale (MARS) and Birchwood Scale (Birchwood), substance use disorders (declarative questionnaire)
Evolution of the patients' number of suicide attempts
Assessed by the Columbia Suicide Severity Rating Scale " (C-SSRS)
Evolution of the patients' suicide risk level
Assessed by the Columbia Suicide Severity Rating Scale " (C-SSRS)
Evolution of the patients' aggressive behaviors
questionnaire
Evolution of the patients' number of hospitalization in psychiatry
number of hospitalization in psychiatry
Evolution of the mental health professionals' beliefs and knowledge about psychoeducation to caregivers
questionnaire
Evolution of the mental health professionals' sense of competence about psychoeducation to caregivers
Self-assessment before, after and 16 months after the training course
Evolution of the mental health professionals' satisfaction of the training course
questionnaire
Evolution of the mental health professionals' satisfaction of the BREF program
questionnaire
Evolution of the psychiatric department organization regarding caregivers interventions
questionnaire
Sustainability of the BREF program in each psychiatric department
Question the referent person at the center to know if the program is still used 3 years after its implementation QUESTION THE REFERENT PERSON AT THE CENTER TO KNOW IF THE PROGRAM IS STILL USED 3 YEARS AFTER ITS IMPLEMENTATION Question the referent perso of the center to know if the program is still used 3 years after its implementation

Full Information

First Posted
August 5, 2021
Last Updated
August 11, 2022
Sponsor
Hôpital le Vinatier
search

1. Study Identification

Unique Protocol Identification Number
NCT05036590
Brief Title
Efficiency Assessment of BREFORM. A Multicentric Stepped-wedge Randomized Control Trial.
Acronym
BREFORM
Official Title
Efficiency Assessment of a Mental Health Professionals' Training Course for a Short Psychoeducational Program (BREF) for Families and Caregivers of Patients With Schizophrenia or First Psychotic Episode.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 5, 2022 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hôpital le Vinatier

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In psychiatry, caregiver burden is associated with excess physical and psychological morbidity in relatives of patients with schizophrenic disorders Single or multi-family psychoeducation for caregivers of patients with schizophrenic disorders or first episode psychosis has a direct benefit on the health of the caregiver and an indirect benefit on the health of the ill family member. It is associated with a reduction in the rate of relapse and re-hospitalization and with better compliance with treatment. For single-family psychoeducation, the number of caregivers to be treated to avoid re-hospitalization of the sick family member is 3. For caregivers, psychoeducation is accompanied by an improvement in knowledge of the disorders and coping strategies. Therefore, international recommendations recommend that psychoeducation for caregivers be systematic, early, and integrated into routine care. Currently, the organization of the French care system does not allow these recommendations to be met. In order to increase the use of psychoeducation in France, early interventions for caregivers must be offered systematically. The effectiveness of early psychoeducation for caregivers needs to be evaluated; only three randomized controlled trials are available in the literature and none have been conducted in France.
Detailed Description
The BREFORM project proposes to train health professionals in an early psychoeducation program, the BREF program, in order to implement it in their structure, and to evaluate its impact on the burden of caregivers of users living with a first psychotic episode or a schizophrenic disorder. Regarding caregivers' outcomes: outcome measures will be assessed at baseline (visit 1, V1), 6 weeks (Visit 2, V2), 6 months (Visit 3, V3), 12 months (Visit 4, V4) after baseline in the active group and in the treatment as usual group Regarding patients' outcomes: outcome measures will be assessed at baseline and 12 months after baseline in the active group and in the treatment as usual group Regarding mental health professionals' outcomes: outcome measures will be assessed before, after and 16 months after the training course Regarding the psychiatric departments' outcomes: outcome measures will be assessed at baseline and 36 months after baseline

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Multicentric Stepped-wedge Randomized Control Trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
206 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
Active Comparator
Arm Description
The design is a stepped-wedge cluster randomized controlled trial. The study will be conducted in 9 centers (clusters) and will be conducted in 6 successive phases of 4 months each. During the first period, groups will be in the control period, then sequentially and according to a randomly defined order, at each time, one group will go into the intervention period after a transition period of 4 months allowing the intervention to be deployed (training of three health professionals for each center and then implementation of the BREF program). Thus, each cluster will belong successively to the control group and the intervention group. During the control period, caregivers will be supported according to the usual practices of each center. During the intervention period, the BREF program will be offered to all eligible caregivers.
Arm Title
intervention group
Arm Type
Experimental
Arm Description
Thus, each cluster will belong successively to the control group and the intervention group. During the intervention period, the BREF program will be offered to all eligible caregivers.
Intervention Type
Other
Intervention Name(s)
control group
Intervention Description
The control group consisted of caregivers included during the control period, before the intervention was deployed, i.e., before the BREF program was implemented by the centers.
Intervention Type
Other
Intervention Name(s)
Intervention group
Intervention Description
The intervention group consists of caregivers included during the intervention period. Caregivers in the intervention group will benefit from the BREF program.
Primary Outcome Measure Information:
Title
Changes in the severity of caregiver burden between V1 and V4 by the Zarit Burden Inventory scale (ZBI)
Description
The ZBI consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. Higher scores indicate greater burden. A score of 17 or more was considered high burden.
Time Frame
one year
Secondary Outcome Measure Information:
Title
Changes in caregiver burden severity at V1,V2 and V3 by the Zarit Burden Inventory (ZBI) scale
Description
The ZBI consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. Higher scores indicate greater burden. A score of 17 or more was considered high burden.
Time Frame
8 months
Title
Evolution of the caregivers' perceived-stress between V1, V2, V3, V4 by the Perceived Stress Scale-14 (PSS-14)
Description
Total score of the PSS can be obtained by summing the 14 items' scores . The total score ranges from 0 to a maximum of 56, a higher score indicating a higher level of perceived stress.
Time Frame
one year
Title
Evolution of the caregivers' mood between V1, V2, V3, V4 by the Center for Epidemiologic Studies-Depression Scale (CES-D)
Description
The CES-D consists of 20 items in a self-report format measuring depressive symptoms experienced in the past week on a 4-point Likert scale ranging from 0 (rarely or none of the time) to 3 (most or all of the time). Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. ... PHQ-9 score ≥10 had a sensitivity of 88% and a specificity of 88% for major depression.
Time Frame
one year
Title
Evolution of the caregivers' family functioning between V1, V2, V3, V4
Description
Assessed by the Family Assessment Device scale (FAD)
Time Frame
one year
Title
Evolution of the caregivers' quality of life between V1, V2, V3, V4
Description
Assessed by the Schizophrenia CareGiver Quality of Life scale (S-CGQoL)
Time Frame
one year
Title
Evolution of the caregivers' sense of competence between V1, V2, V3, V4
Description
assessed by the Sense of Competence Questionnaire scale (SCQ)
Time Frame
one year
Title
Evolution of the caregivers' number of consultations with the general practitioner (GP)
Description
Change in number of consultations with the general practitioner (GP) n the 12 months prior to inclusion compared to the 12 months following inclusion
Time Frame
12 months period before baseline assessment versus 12 months period after baseline assessment
Title
Evolution of the caregivers' number of days off work
Description
Change in number the caregivers' number of days off work in the 12 months prior to inclusion compared to the 12 months following inclusion
Time Frame
12 months period before baseline assessment vs. 12 months period after baseline assessment
Title
Evolution of the caregivers' number of days on long-term leave or disability
Description
Change in the number of long-term leaves of absence or disability related to the caregiver situation in the 12 months prior to inclusion compared to the 12 months following inclusion
Time Frame
12 months period before baseline assessment vs. 12 months period after baseline assessment
Title
Evolution of the caregivers' number of work days
Description
Change in the number of work days related to the caregiver situation in the 12 months prior to inclusion compared to the 12 months following inclusion
Time Frame
12 months
Title
Evolution of the caregivers' willingness to pay someone to replace them in their caring activities during one hour
Description
Change in caregivers' willingness to pay someone to replace them in their caregiving activities for one hour in the 12 months prior to inclusion versus 12 months after inclusion.
Time Frame
12 months
Title
Evolution of the caregivers' number of suicide attempts assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
Description
The Columbia Suicide Severity Rating Scale (C-SSRS) is a measure used to identify and assess individuals at risk for suicide. Questions are phrased for use in an interview format, but can be completed as a self-report measure if necessary. The score is created at each assessment for each patient and is used for determining treatment emergence. Suicidal Ideation Score: The maximum suicidal ideation category (1-5 on the C- SSRS) present at the assessment. Assign a score of 0 if no ideation is present.
Time Frame
12 months period before baseline assessment vs. 12 months period after baseline assessment
Title
caregivers' satisfaction
Description
questionnaire
Time Frame
12 months
Title
Evolution of the caregivers' living status (shared or non-shared household) between V1, V2, V3, V4
Description
questionnaire
Time Frame
12 months
Title
Evolution of the caregivers' informal caregiving activities between V1, V2, V3, V4
Description
questionnaire
Time Frame
12 months
Title
Evolution of the caregivers' number of hours spent providing informal caregiving between V1, V2, V3, V4
Description
questionnaire
Time Frame
12 months
Title
Evolution of the patients' psychotic symptoms severity between baseline and 12 months after baseline assessed by the Positive And Negative Syndrome Scale (PANSS)
Description
PANSS items are rated on a 7-point scale (1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, and 7=extreme); because the absence of symptoms is equal to 1 point, the lowest possible total score on both PANSS scales is 7.
Time Frame
12 months period before baseline assessment vs. 12 months period after baseline assessment
Title
Evolution of the patients' functioning level between baseline and 12 months after baseline
Description
Assessed by the Global Assessment of Functionning scale (GAF)
Time Frame
Baseline assessment and 12 months after baseline assessment
Title
Evolution of the patients' functioning level assessed by the Personal and social Performance scale (PSP)
Description
The patient's degree of severity in the four domains is to be rated on a six-point scale from absent (which means no problems on this dimension) over mild, manifest, marked, severe to very severe difficulties in the given area. Out of the ratings on the four subdimensions, one total score on a 100-point scale can be created. A variation of eight points is already to be classified as a clinically relevant difference. The items "self-care" and "disturbing and aggressive behavior" are of greater concern for patients with acute
Time Frame
Baseline assessment and 12 months after baseline assessment
Title
Evolution of the patients' quality of life between baseline and 12 months after baseline
Description
Assessed by the Schizophrenia-quality of Life scale (S-QoL)
Time Frame
Baseline assessment and 12 months after baseline assessment
Title
Evolution of the patients' clinical severity between baseline and 12 months after baseline
Description
Assessed by the Clinical Global Impression (CGI)
Time Frame
Baseline assessment and 12 months after baseline assessment
Title
Evolution of the patients' depressive symptoms between baseline and 12 months after baseline
Description
Assessed by the Calgary Depression Scale for Schizophrenia scale (CDSS)
Time Frame
Baseline assessment and 12 months after baseline assessment
Title
Evolution of the patients' relapse risk factors between baseline and 12 months after baseline
Description
Composite score assessed by the Medication Adherence Rating Scale (MARS) and Birchwood Scale (Birchwood), substance use disorders (declarative questionnaire)
Time Frame
Baseline assessment and 12 months after baseline assessment
Title
Evolution of the patients' number of suicide attempts
Description
Assessed by the Columbia Suicide Severity Rating Scale " (C-SSRS)
Time Frame
12 months period before baseline assessment vs. 12 months period after baseline assessment
Title
Evolution of the patients' suicide risk level
Description
Assessed by the Columbia Suicide Severity Rating Scale " (C-SSRS)
Time Frame
Baseline assessment and 12 months after baseline assessment
Title
Evolution of the patients' aggressive behaviors
Description
questionnaire
Time Frame
12 months period before baseline assessment vs. 12 months period after baseline assessment
Title
Evolution of the patients' number of hospitalization in psychiatry
Description
number of hospitalization in psychiatry
Time Frame
12 months period before baseline assessment vs. 12 months period after baseline assessment
Title
Evolution of the mental health professionals' beliefs and knowledge about psychoeducation to caregivers
Description
questionnaire
Time Frame
Assessed before, after and 16 months after the training course
Title
Evolution of the mental health professionals' sense of competence about psychoeducation to caregivers
Description
Self-assessment before, after and 16 months after the training course
Time Frame
Assessed before, after and 16 months after the training course
Title
Evolution of the mental health professionals' satisfaction of the training course
Description
questionnaire
Time Frame
Assessed after and 16 months after the training course
Title
Evolution of the mental health professionals' satisfaction of the BREF program
Description
questionnaire
Time Frame
Assessed 16 months after the training course
Title
Evolution of the psychiatric department organization regarding caregivers interventions
Description
questionnaire
Time Frame
Assessed at baseline and 36 months after baseline
Title
Sustainability of the BREF program in each psychiatric department
Description
Question the referent person at the center to know if the program is still used 3 years after its implementation QUESTION THE REFERENT PERSON AT THE CENTER TO KNOW IF THE PROGRAM IS STILL USED 3 YEARS AFTER ITS IMPLEMENTATION Question the referent perso of the center to know if the program is still used 3 years after its implementation
Time Frame
Assessed 36 months after baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: people over 18yo first-degree relatives (parents, siblings, children) or spouse of the patient primary caregiver of a patient with schizophrenic disorders or first psychotic episode (DSM5) consenting to participate to the study Exclusion Criteria: mental disorder on Axis I having already benefited from a family intervention such as psychoeducation caring for several people with severe psychiatric disorders receiving income for the caring activities being legally responsible of the patient having difficulty understanding fluent French illiterate
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Romain REY, MD, PhD
Phone
+33437915495
Email
romain.rey@ch-le-vinatier.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Anne-Lise BOHEC, PhD
Phone
+33437915495
Email
Anne-lise.BOHEC@ch-le-vinatier.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Romain REY, MD, PhD
Organizational Affiliation
CH LE VINATIER
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hopital Vinatier
City
Bron
ZIP/Postal Code
69678
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ROMAIN REY, PH
Phone
+33(0)437915280
Email
Romain.Rey@ch-le-vinatier.fr
First Name & Middle Initial & Last Name & Degree
VERONIQUE VIAL
Phone
+33(0)437915531
Email
Veronique.Vial@ch-le-vinatier.fr

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Efficiency Assessment of BREFORM. A Multicentric Stepped-wedge Randomized Control Trial.

We'll reach out to this number within 24 hrs